{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:49:44Z","timestamp":1793407784501,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"8112","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Developing safe and effective pain medications is an ongoing challenge for human health. Agonists for the \u00b5-opioid receptor (MOR) are essential pain medications, but their high intrinsic efficacy also induces adverse side effects, including respiratory depression, constipation, tolerance, dependence, withdrawal and addiction\n                    <jats:sup>1\u20137<\/jats:sup>\n                    . Strategies to limit adverse effects traditionally include developing MOR agonists that have low intrinsic efficacy or that preferentially activate G-protein signalling over \u03b2-arrestin signalling\n                    <jats:sup>8<\/jats:sup>\n                    . Here we identify a novel MOR agonist with supramaximal intrinsic efficacy and a unique pharmacological profile that produced effective analgesia in rodents with minimal adverse effects.\n                    <jats:italic>N<\/jats:italic>\n                    -desethyl-fluornitrazene (DFNZ) was derived from a class of synthetic benzimidazole opioids called nitazenes. DFNZ has impaired brain penetrance, a unique spatiotemporal MOR cellular signalling profile, and diminished efficacy at the MOR\u2013galanin 1 receptor (GAL1) heteromer. DFNZ does not induce respiratory depression, tolerance or MOR downregulation after repeated exposure. Compared with other MOR agonists, DFNZ has limited effects on dopamine neurotransmission in nucleus accumbens and weaker reinforcing effects in the drug self-administration procedure. These results provide novel insights about MOR and nitazene pharmacology, have important implications for pain and addiction treatment, and challenge the prevailing dogma that high-efficacy MOR agonists cannot constitute safe and effective therapeutic agents.\n                  <\/jats:p>","DOI":"10.1038\/s41586-026-10299-9","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:02:46Z","timestamp":1775055766000},"page":"1393-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A \u00b5-opioid receptor superagonist analgesic with minimal adverse effects"],"prefix":"10.1038","volume":"652","author":[{"given":"Juan L.","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilya N.","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5499-4050","authenticated-orcid":false,"given":"Zachary J.","family":"Frangos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Sulima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2610-680X","authenticated-orcid":false,"given":"Michael J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reece C.","family":"Budinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca M.","family":"Giosan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-0079","authenticated-orcid":false,"given":"Tongzhen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-5891","authenticated-orcid":false,"given":"Oscar","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4268-5904","authenticated-orcid":false,"given":"Anna E.","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Bossert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiera E.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Bonbrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9972-8187","authenticated-orcid":false,"given":"Amelie","family":"Essmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-7531","authenticated-orcid":false,"given":"Zelai M.","family":"Gar\u00e7on-Poca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3505-4318","authenticated-orcid":false,"given":"Shinbe","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Noya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5180-8948","authenticated-orcid":false,"given":"Feonil","family":"Limiac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant C.","family":"Glatfelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina A.","family":"Mullarkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dain R.","family":"Brademan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-0246","authenticated-orcid":false,"given":"Garrett","family":"Enten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1334-6069","authenticated-orcid":false,"given":"William","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4275-9995","authenticated-orcid":false,"given":"Ingrid","family":"Schoenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Dannals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-096X","authenticated-orcid":false,"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"H\u00fcttenhain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1747-1779","authenticated-orcid":false,"given":"Sergi","family":"Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Kiyatkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-0151","authenticated-orcid":false,"given":"Jordi","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-3319","authenticated-orcid":false,"given":"Yavin","family":"Shaham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venetia","family":"Zachariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-7846","authenticated-orcid":false,"given":"Georgios","family":"Skiniotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1147-9147","authenticated-orcid":false,"given":"Kenner C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-4917","authenticated-orcid":false,"given":"Michael","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"10299_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/ph14111091","volume":"14","author":"AK Paul","year":"2021","unstructured":"Paul, A. K. et al. Opioid analgesia and opioid-induced adverse effects: a review. Pharmaceuticals 14, 1091 (2021).","journal-title":"Pharmaceuticals"},{"key":"10299_CR2","first-page":"L267","volume":"328","author":"BA Baldo","year":"2025","unstructured":"Baldo, B. A. Opioid-induced respiratory depression: clinical aspects and pathophysiology of the respiratory network effects. Am. J. Physiol. 328, L267\u2013L289 (2025).","journal-title":"Am. J. Physiol."},{"key":"10299_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/AJP.0b013e31816b2f43","volume":"24","author":"LF Chu","year":"2008","unstructured":"Chu, L. F., Angst, M. S. & Clark, D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin. J. Pain 24, 479\u2013496 (2008).","journal-title":"Clin. J. Pain"},{"key":"10299_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","volume":"33","author":"S Mercadante","year":"2019","unstructured":"Mercadante, S., Arcuri, E. & Santoni, A. Opioid-induced tolerance and hyperalgesia. CNS Drugs 33, 943\u2013955 (2019).","journal-title":"CNS Drugs"},{"key":"10299_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-017-0080-3","volume":"14","author":"CP Schaefer","year":"2017","unstructured":"Schaefer, C. P., Tome, M. E. & Davis, T. P. The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS 14, 32 (2017).","journal-title":"Fluids Barriers CNS"},{"key":"10299_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","volume":"58","author":"P Skolnick","year":"2018","unstructured":"Skolnick, P. The opioid epidemic: crisis and solutions. Annu. Rev. Pharmacol. Toxicol. 58, 143\u2013159 (2018).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10299_CR7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","volume":"99","author":"ND Volkow","year":"2019","unstructured":"Volkow, N. D., Michaelides, M. & Baler, R. The neuroscience of drug reward and addiction. Physiol. Rev. 99, 2115\u20132140 (2019).","journal-title":"Physiol. Rev."},{"key":"10299_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14728222.2019.1586882","volume":"23","author":"AT Ehrlich","year":"2019","unstructured":"Ehrlich, A. T., Kieffer, B. L. & Darcq, E. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin. Ther. Targets 23, 315\u2013326 (2019).","journal-title":"Expert Opin. Ther. Targets"},{"key":"10299_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-025-03280-5","author":"M Basu","year":"2025","unstructured":"Basu, M. Dangerous \u2018nitazene\u2019 opioids are on the rise: researchers are worried. Nature https:\/\/doi.org\/10.1038\/d41586-025-03280-5 (2025).","journal-title":"Nature"},{"key":"10299_CR10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","volume":"12","author":"I Ujv\u00e1ry","year":"2021","unstructured":"Ujv\u00e1ry, I. et al. DARK classics in chemical neuroscience: etonitazene and related benzimidazoles. ACS Chem. Neurosci. 12, 1072\u20131092 (2021).","journal-title":"ACS Chem. Neurosci."},{"key":"10299_CR11","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00213-023-06451-2","volume":"240","author":"GC Glatfelter","year":"2023","unstructured":"Glatfelter, G. C. et al. Alkoxy chain length governs the potency of 2-benzylbenzimidazole \u2018nitazene\u2019 opioids associated with human overdose. Psychopharmacology 240, 2573\u20132584 (2023).","journal-title":"Psychopharmacology"},{"key":"10299_CR12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","volume":"12","author":"MM Vandeputte","year":"2021","unstructured":"Vandeputte, M. M. et al. Synthesis, chemical characterization, and \u03bc-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids. ACS Chem. Neurosci. 12, 1241\u20131251 (2021).","journal-title":"ACS Chem. Neurosci."},{"key":"10299_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/bja\/57.2.192","volume":"57","author":"RA Boas","year":"1985","unstructured":"Boas, R. A. & Villiger, J. W. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br. J. Anaesth. 57, 192\u2013196 (1985).","journal-title":"Br. J. Anaesth."},{"key":"10299_CR14","doi-asserted-by":"crossref","unstructured":"Ballesteros, J. A. & Weinstein, H. in Methods in Neurosciences Vol. 25 (ed. Sealfon S. C.) 366\u2013428 (Academic Press, 1995).","DOI":"10.1016\/S1043-9471(05)80049-7"},{"key":"10299_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nchembio.2431","volume":"13","author":"JR Lane","year":"2017","unstructured":"Lane, J. R., May, L. T., Parton, R. G., Sexton, P. M. & Christopoulos, A. A kinetic view of GPCR allostery and biased agonism. Nat. Chem. Biol. 13, 929\u2013937 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"10299_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.neuron.2018.04.021","volume":"98","author":"M Stoeber","year":"2018","unstructured":"Stoeber, M. et al. A genetically encoded biosensor reveals location bias of opioid drug action. Neuron 98, 963\u2013976.e965 (2018).","journal-title":"Neuron"},{"key":"10299_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/s41589-024-01588-3","volume":"20","author":"BJ Polacco","year":"2024","unstructured":"Polacco, B. J. et al. Profiling the proximal proteome of the activated \u03bc-opioid receptor. Nat. Chem. Biol. 20, 1133\u20131143 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"10299_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1124\/jpet.121.001045","volume":"382","author":"EJ Santos","year":"2022","unstructured":"Santos, E. J., Banks, M. L. & Negus, S. S. Role of efficacy as a determinant of locomotor activation by mu opioid receptor ligands in female and male mice. J. Pharmacol. Exp. Ther. 382, 44\u201353 (2022).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10299_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","volume":"30","author":"VW Pike","year":"2009","unstructured":"Pike, V. W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci. 30, 431\u2013440 (2009).","journal-title":"Trends Pharmacol. Sci."},{"key":"10299_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.2174\/1570159X15666170504095823","volume":"15","author":"C Chaves","year":"2017","unstructured":"Chaves, C., Remiao, F., Cisternino, S. & Decleves, X. Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. Curr. Neuropharmacol. 15, 1156\u20131173 (2017).","journal-title":"Curr. Neuropharmacol."},{"key":"10299_CR21","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.3390\/pharmaceutics15102473","volume":"15","author":"MM Parvez","year":"2023","unstructured":"Parvez, M. M., Sadighi, A., Ahn, Y., Keller, S. F. & Enoru, J. O. Uptake transporters at the blood\u2013brain barrier and their role in brain drug disposition. Pharmaceutics 15, 2473 (2023).","journal-title":"Pharmaceutics"},{"key":"10299_CR22","doi-asserted-by":"publisher","first-page":"C678","DOI":"10.1152\/ajpcell.00090.2006","volume":"291","author":"M Hiasa","year":"2006","unstructured":"Hiasa, M., Matsumoto, T., Komatsu, T. & Moriyama, Y. Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. Am. J. Physiol. 291, C678\u2013C686 (2006).","journal-title":"Am. J. Physiol."},{"key":"10299_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/164_2021_448","volume":"266","author":"RD Betterton","year":"2021","unstructured":"Betterton, R. D., Davis, T. P. & Ronaldson, P. T. Organic cation transporter (OCT\/OCTN) expression at brain barrier sites: focus on CNS drug delivery. Handb. Exp. Pharmacol. 266, 301\u2013328 (2021).","journal-title":"Handb. Exp. Pharmacol."},{"key":"10299_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/17425247.2016.1092519","volume":"13","author":"AD Kulkarni","year":"2016","unstructured":"Kulkarni, A. D., Patel, H. M., Surana, S. J., Belgamwar, V. S. & Pardeshi, C. V. Brain-blood ratio: implications in brain drug delivery. Expert Opin. Drug Deliv. 13, 85\u201392 (2016).","journal-title":"Expert Opin. Drug Deliv."},{"key":"10299_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/toxsci\/kfy093","volume":"164","author":"C Yu","year":"2018","unstructured":"Yu, C., Yuan, M., Yang, H., Zhuang, X. & Li, H. P-glycoprotein on blood-brain barrier plays a vital role in fentanyl brain exposure and respiratory toxicity in rats. Toxicol. Sci. 164, 353\u2013362 (2018).","journal-title":"Toxicol. Sci."},{"key":"10299_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","volume":"58","author":"M Kinnunen","year":"2019","unstructured":"Kinnunen, M., Piirainen, P., Kokki, H., Lammi, P. & Kokki, M. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin. Pharmacokinet. 58, 705\u2013725 (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"10299_CR27","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/bcp.13368","volume":"83","author":"HV Kalluri","year":"2017","unstructured":"Kalluri, H. V., Zhang, H., Caritis, S. N. & Venkataramanan, R. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. Br. J. Clin. Pharmacol. 83, 2458\u20132473 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10299_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00414-021-02502-5","volume":"135","author":"S Iwersen-Bergmann","year":"2021","unstructured":"Iwersen-Bergmann, S. et al. Brain\/blood ratios of methadone and ABCB1 polymorphisms in methadone-related deaths. Int. J. Legal Med. 135, 473\u2013482 (2021).","journal-title":"Int. J. Legal Med."},{"key":"10299_CR29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/cpt.2227","volume":"110","author":"F Storelli","year":"2021","unstructured":"Storelli, F., Anoshchenko, O. & Unadkat, J. D. Successful prediction of human steady-state unbound brain-to-plasma concentration ratio of P-gp substrates using the proteomics-informed relative expression factor approach. Clin. Pharmacol. Ther. 110, 432\u2013442 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"10299_CR30","doi-asserted-by":"publisher","first-page":"110412","DOI":"10.1016\/j.neuropharm.2025.110412","volume":"271","author":"FG Limiac","year":"2025","unstructured":"Limiac, F. G., Noya, M. R. & Kiyatkin, E. A. Comparison of fentanyl-induced brain oxygen responses following intravenous and intraperitoneal injections in rats. Neuropharmacology 271, 110412 (2025).","journal-title":"Neuropharmacology"},{"key":"10299_CR31","doi-asserted-by":"publisher","first-page":"109939","DOI":"10.1016\/j.drugalcdep.2023.109939","volume":"249","author":"MM Vandeputte","year":"2023","unstructured":"Vandeputte, M. M. et al. Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. Drug Alcohol Depend. 249, 109939 (2023).","journal-title":"Drug Alcohol Depend."},{"key":"10299_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejphar.2005.09.060","volume":"525","author":"V Panchal","year":"2005","unstructured":"Panchal, V., Taraschenko, O. D., Maisonneuve, I. M. & Glick, S. D. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. Eur. J. Pharmacol. 525, 98\u2013104 (2005).","journal-title":"Eur. J. Pharmacol."},{"key":"10299_CR33","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.ynstr.2021.100325","volume":"14","author":"RCN Marchette","year":"2021","unstructured":"Marchette, R. C. N. et al. \u03ba-Opioid receptor antagonism reverses heroin withdrawal-induced hyperalgesia in male and female rats. Neurobiol. Stress 14, 100325 (2021).","journal-title":"Neurobiol. Stress"},{"key":"10299_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/00000539-200205000-00040","volume":"94","author":"JP Laulin","year":"2002","unstructured":"Laulin, J. P. et al. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth. Analg. 94, 1263\u20131269 (2002).","journal-title":"Anesth. Analg."},{"key":"10299_CR35","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.neubiorev.2010.10.012","volume":"35","author":"EC O\u2019Connor","year":"2011","unstructured":"O\u2019Connor, E. C., Chapman, K., Butler, P. & Mead, A. N. The predictive validity of the rat self-administration model for abuse liability. Neurosci. Biobehav. Rev. 35, 912\u2013938 (2011).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10299_CR36","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","volume":"105","author":"LP Carter","year":"2009","unstructured":"Carter, L. P. & Griffiths, R. R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. 105, S14\u2013S25 (2009).","journal-title":"Drug Alcohol Depend."},{"key":"10299_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0893-133X(95)00274-H","volume":"14","author":"NK Mello","year":"1996","unstructured":"Mello, N. K. & Negus, S. S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14, 375\u2013424 (1996).","journal-title":"Neuropsychopharmacology"},{"key":"10299_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.54.1.1","volume":"54","author":"U Shalev","year":"2002","unstructured":"Shalev, U., Grimm, J. W. & Shaham, Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev. 54, 1\u201342 (2002).","journal-title":"Pharmacol Rev."},{"key":"10299_CR39","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1016\/j.pharmr.2024.100022","volume":"77","author":"JJ Chow","year":"2025","unstructured":"Chow, J. J. et al. Neurobiology of the incubation of drug craving: an update. Pharmacol Rev. 77, 100022 (2025).","journal-title":"Pharmacol Rev."},{"key":"10299_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-002-1224-x","volume":"168","author":"Y Shaham","year":"2003","unstructured":"Shaham, Y., Shalev, U., Lu, L., de Wit, H. & Stewart, J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168, 3\u201320 (2003).","journal-title":"Psychopharmacology"},{"key":"10299_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrn1406","volume":"5","author":"RA Wise","year":"2004","unstructured":"Wise, R. A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 5, 483\u2013494 (2004).","journal-title":"Nat. Rev. Neurosci."},{"key":"10299_CR42","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1046\/j.1360-0443.95.8s2.1.x","volume":"95","author":"AA Grace","year":"2000","unstructured":"Grace, A. A. The tonic\/phase model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95, S119\u2013S128 (2000).","journal-title":"Addiction"},{"key":"10299_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/7854_2009_27","volume":"3","author":"I Willuhn","year":"2010","unstructured":"Willuhn, I., Wanat, M. J., Clark, J. J. & Phillips, P. E. Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr. Top. Behav. Neurosci. 3, 29\u201371 (2010).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10299_CR44","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41593-018-0211-4","volume":"21","author":"GJ Broussard","year":"2018","unstructured":"Broussard, G. J. et al. In vivo measurement of afferent activity with axon-specific calcium imaging. Nat. Neurosci. 21, 1272\u20131280 (2018).","journal-title":"Nat. Neurosci."},{"key":"10299_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41581-3","volume":"14","author":"AG Salinas","year":"2023","unstructured":"Salinas, A. G. et al. Distinct sub-second dopamine signaling in dorsolateral striatum measured by a genetically-encoded fluorescent sensor. Nat. Commun. 14, 5915 (2023).","journal-title":"Nat. Commun."},{"key":"10299_CR46","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI126912","volume":"129","author":"NS Cai","year":"2019","unstructured":"Cai, N. S. et al. Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids. J. Clin. Invest. 129, 2730\u20132744 (2019).","journal-title":"J. Clin. Invest."},{"key":"10299_CR47","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41380-023-02353-z","volume":"29","author":"MR Levinstein","year":"2024","unstructured":"Levinstein, M. R. et al. Unique pharmacodynamic properties and low abuse liability of the \u00b5-opioid receptor ligand (S)-methadone. Mol. Psychiatry 29, 624\u2013632 (2024).","journal-title":"Mol. Psychiatry"},{"key":"10299_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02473-8","volume":"13","author":"MJ Shram","year":"2023","unstructured":"Shram, M. J. et al. The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. Transl. Psychiatry 13, 192 (2023).","journal-title":"Transl. Psychiatry"},{"key":"10299_CR49","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.tips.2020.09.009","volume":"41","author":"A Gillis","year":"2020","unstructured":"Gillis, A. et al. Critical assessment of G protein-biased agonism at the \u03bc-opioid receptor. Trends Pharmacol. Sci. 41, 947\u2013959 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"10299_CR50","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nn1579","volume":"8","author":"BJ Everitt","year":"2005","unstructured":"Everitt, B. J. & Robbins, T. W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8, 1481\u20131489 (2005).","journal-title":"Nat. Neurosci."},{"key":"10299_CR51","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","volume":"26","author":"J Bonaventura","year":"2021","unstructured":"Bonaventura, J. et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol. Psychiatry 26, 6704\u20136722 (2021).","journal-title":"Mol. Psychiatry"},{"key":"10299_CR52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00213-004-1891-x","volume":"176","author":"JH Broadbear","year":"2004","unstructured":"Broadbear, J. H., Winger, G. & Woods, J. H. Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary\u2013adrenal axis in rhesus monkeys. Psychopharmacology 176, 398\u2013406 (2004).","journal-title":"Psychopharmacology"},{"key":"10299_CR53","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","volume":"151","author":"TT Le","year":"2022","unstructured":"Le, T. T. et al. The abuse liability of ketamine: a scoping review of preclinical and clinical studies. J. Psychiatr. Res. 151, 476\u2013496 (2022).","journal-title":"J. Psychiatr. Res."},{"key":"10299_CR54","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04993-7","volume":"608","author":"LD Simmler","year":"2022","unstructured":"Simmler, L. D. et al. Dual action of ketamine confines addiction liability. Nature 608, 368\u2013373 (2022).","journal-title":"Nature"},{"key":"10299_CR55","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1038\/s41380-025-02931-3","volume":"30","author":"A Rizzo","year":"2025","unstructured":"Rizzo, A. et al. The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors. Mol. Psychiatry 30, 3443\u20133454 (2025).","journal-title":"Mol. Psychiatry"},{"key":"10299_CR56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/1874473710902020195","volume":"2","author":"MJ Wanat","year":"2009","unstructured":"Wanat, M. J., Willuhn, I., Clark, J. J. & Phillips, P. E. Phasic dopamine release in appetitive behaviors and drug addiction. Curr. Drug Abuse Rev. 2, 195\u2013213 (2009).","journal-title":"Curr. Drug Abuse Rev."},{"key":"10299_CR57","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fnbeh.2010.00170","volume":"4","author":"JA Beeler","year":"2010","unstructured":"Beeler, J. A., Daw, N., Frazier, C. R. & Zhuang, X. Tonic dopamine modulates exploitation of reward learning. Front. Behav. Neurosci. 4, 170 (2010).","journal-title":"Front. Behav. Neurosci."},{"key":"10299_CR58","unstructured":"Flunitazene has anyone tried it? Reddit.com https:\/\/www.reddit.com\/r\/Rc_Opioids_Italy\/comments\/1fxcuvk\/comment\/lqlpg1q\/ (2025)."},{"key":"10299_CR59","volume":"2","author":"AKR Ting","year":"2012","unstructured":"Ting, A. K. R. & van der Kooy, D. The neurobiology of opiate motivation. Cold Spring Harb. Perspect. Med. 2, a012096 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10299_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5055\/jom.2011.0049","volume":"7","author":"N Vadivelu","year":"2011","unstructured":"Vadivelu, N., Mitra, S. & Hines, R. L. Peripheral opioid receptor agonists for analgesia: a comprehensive review. J. Opioid Manag. 7, 55\u201368 (2011).","journal-title":"J. Opioid Manag."},{"key":"10299_CR61","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-025-09677-6","volume":"648","author":"S Khan","year":"2025","unstructured":"Khan, S. et al. Structural snapshots capture nucleotide release at the \u03bc-opioid receptor. Nature 648, 755\u2013763 (2025).","journal-title":"Nature"},{"key":"10299_CR62","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2174\/1381612043453036","volume":"10","author":"DL DeHaven-Hudkins","year":"2004","unstructured":"DeHaven-Hudkins, D. L. & Dolle, R. E. Peripherally restricted opioid agonists as novel analgesic agents. Curr. Pharm. Des. 10, 743\u2013757 (2004).","journal-title":"Curr. Pharm. Des."},{"key":"10299_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/pharmrev.121.000367","volume":"74","author":"C Nicolas","year":"2022","unstructured":"Nicolas, C. et al. Sex differences in opioid and psychostimulant craving and relapse: a critical review. Pharmacol. Rev. 74, 119\u2013140 (2022).","journal-title":"Pharmacol. Rev."},{"key":"10299_CR64","doi-asserted-by":"publisher","first-page":"173890","DOI":"10.1016\/j.pbb.2024.173890","volume":"245","author":"AE Barattini","year":"2024","unstructured":"Barattini, A. E., Gilpin, N. W. & Pahng, A. R. Chronic inflammatory pain reduces fentanyl intake during early acquisition of fentanyl self-administration, but does not change motivation to take fentanyl in male and female rats. Pharmacol. Biochem. Behav. 245, 173890 (2024).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10299_CR65","doi-asserted-by":"publisher","unstructured":"Burgess, G. E., Traynor, J. R. & Jutkiewicz, E. M. The effects of chronic neuropathic pain on the self-administration of highly potent MOR agonist, fentanyl. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.11.19.624389 (2024).","DOI":"10.1101\/2024.11.19.624389"},{"key":"10299_CR66","doi-asserted-by":"publisher","first-page":"109512","DOI":"10.1016\/j.neuropharm.2023.109512","volume":"231","author":"AE Barattini","year":"2023","unstructured":"Barattini, A. E. et al. Chronic inflammatory pain promotes place preference for fentanyl in male rats but does not change fentanyl self-administration in male and female rats. Neuropharmacology 231, 109512 (2023).","journal-title":"Neuropharmacology"},{"key":"10299_CR67","doi-asserted-by":"publisher","first-page":"12217","DOI":"10.1523\/JNEUROSCI.1053-15.2015","volume":"35","author":"L Hip\u00f3lito","year":"2015","unstructured":"Hip\u00f3lito, L. et al. Inflammatory pain promotes increased opioid self-administration: role of dysregulated ventral tegmental area \u03bc opioid receptors. J. Neurosci. 35, 12217\u201312231 (2015).","journal-title":"J. Neurosci."},{"key":"10299_CR68","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00213-021-05816-9","volume":"238","author":"DJ Reiner","year":"2021","unstructured":"Reiner, D. J. et al. Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats. Psychopharmacology 238, 1885\u20131897 (2021).","journal-title":"Psychopharmacology"},{"key":"10299_CR69","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","volume":"16","author":"RHJ Olsen","year":"2020","unstructured":"Olsen, R. H. J. et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat. Chem. Biol. 16, 841\u2013849 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"10299_CR70","doi-asserted-by":"publisher","first-page":"19989","DOI":"10.1074\/jbc.M117.800698","volume":"292","author":"H Yano","year":"2017","unstructured":"Yano, H. et al. Development of novel biosensors to study receptor-mediated activation of the G-protein \u03b1 subunits Gs and Golf. J. Biol. Chem. 292, 19989\u201319998 (2017).","journal-title":"J. Biol. Chem."},{"key":"10299_CR71","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1124\/mol.113.088880","volume":"85","author":"ET van der Westhuizen","year":"2014","unstructured":"van der Westhuizen, E. T., Breton, B., Christopoulos, A. & Bouvier, M. Quantification of ligand bias for clinically relevant \u03b22-adrenergic receptor ligands: implications for drug taxonomy. Mol. Pharmacol. 85, 492\u2013509 (2014).","journal-title":"Mol. Pharmacol."},{"key":"10299_CR72","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14886","volume":"524","author":"W Huang","year":"2015","unstructured":"Huang, W. et al. Structural insights into \u00b5-opioid receptor activation. Nature 524, 315\u2013321 (2015).","journal-title":"Nature"},{"key":"10299_CR73","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-4939-2914-6_3","volume":"1335","author":"A Peisley","year":"2015","unstructured":"Peisley, A. & Skiniotis, G. 2D projection analysis of GPCR complexes by negative stain electron microscopy. Methods Mol. Biol. 1335, 29\u201338 (2015).","journal-title":"Methods Mol. Biol."},{"key":"10299_CR74","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1042\/BCJ20210708","volume":"478","author":"D Kimanius","year":"2021","unstructured":"Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools for automated cryo-EM single-particle analysis in RELION-4.0. Biochem J. 478, 4169\u20134185 (2021).","journal-title":"Biochem J."},{"key":"10299_CR75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"10299_CR76","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"10299_CR77","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"10299_CR78","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"10299_CR79","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D"},{"key":"10299_CR80","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.str.2020.04.018","volume":"28","author":"MJ Robertson","year":"2020","unstructured":"Robertson, M. J., van Zundert, G. C. P., Borrelli, K. & Skiniotis, G. GemSpot: a pipeline for robust modeling of ligands into cryo-EM maps. Structure 28, 707\u2013716.e703 (2020).","journal-title":"Structure"},{"key":"10299_CR81","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s44320-024-00049-2","volume":"20","author":"X Zhong","year":"2024","unstructured":"Zhong, X. et al. A proximity proteomics pipeline with improved reproducibility and throughput. Mol. Syst. Biol. 20, 952\u2013971 (2024).","journal-title":"Mol. Syst. Biol."},{"key":"10299_CR82","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1021\/acs.jproteome.2c00834","volume":"22","author":"D Kohler","year":"2023","unstructured":"Kohler, D. et al. MSstats version 4.0: statistical analyses of quantitative mass spectrometry-based proteomic experiments with chromatography-based quantification at scale. J. Proteome Res. 22, 1466\u20131482 (2023).","journal-title":"J. Proteome Res."},{"key":"10299_CR83","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2337\/db24-0175","volume":"73","author":"A Bonifazi","year":"2024","unstructured":"Bonifazi, A. et al. Development of novel tools for dissection of central versus peripheral dopamine D2-like receptor signaling in dysglycemia. Diabetes 73, 1411\u20131425 (2024).","journal-title":"Diabetes"},{"key":"10299_CR84","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1021\/acs.jmedchem.1c01709","volume":"65","author":"I Berhane","year":"2022","unstructured":"Berhane, I. et al. Thieno[2,3-d]pyrimidine-based positive allosteric modulators of human Mas-related G protein-coupled receptor X1 (MRGPRX1). J. Med. Chem. 65, 3218\u20133228 (2022).","journal-title":"J. Med. Chem."},{"key":"10299_CR85","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/jps.23818","volume":"103","author":"HM Weiss","year":"2014","unstructured":"Weiss, H. M. & Gatlik, E. Equilibrium gel filtration to measure plasma protein binding of very highly bound drugs. J. Pharm. Sci. 103, 752\u2013759 (2014).","journal-title":"J. Pharm. Sci."},{"key":"10299_CR86","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.xphs.2018.10.004","volume":"108","author":"J Isbell","year":"2019","unstructured":"Isbell, J. et al. Plasma protein binding of highly bound drugs determined with equilibrium gel filtration of nonradiolabeled compounds and LC-MS\/MS detection. J. Pharm. Sci. 108, 1053\u20131060 (2019).","journal-title":"J. Pharm. Sci."},{"key":"10299_CR87","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00213-020-05525-9","volume":"237","author":"F Sakloth","year":"2020","unstructured":"Sakloth, F. et al. HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice. Psychopharmacology 237, 2139\u20132149 (2020).","journal-title":"Psychopharmacology"},{"key":"10299_CR88","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41593-023-01350-3","volume":"26","author":"KD Pryce","year":"2023","unstructured":"Pryce, K. D. et al. Oxycodone withdrawal induces HDAC1\/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury. Nat. Neurosci. 26, 1229\u20131244 (2023).","journal-title":"Nat. Neurosci."},{"key":"10299_CR89","doi-asserted-by":"publisher","first-page":"8291","DOI":"10.1523\/JNEUROSCI.3154-18.2019","volume":"39","author":"K Avrampou","year":"2019","unstructured":"Avrampou, K. et al. RGS4 maintains chronic pain symptoms in rodent models. J. Neurosci. 39, 8291\u20138304 (2019).","journal-title":"J. Neurosci."},{"key":"10299_CR90","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41386-022-01507-x","volume":"48","author":"E Ventriglia","year":"2023","unstructured":"Ventriglia, E. et al. Essential role of P-glycoprotein in the mechanism of action of oliceridine. Neuropsychopharmacology 48, 831\u2013842 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"10299_CR91","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0151-17.2017","volume":"4","author":"E Solis Jr","year":"2017","unstructured":"Solis, E. Jr, Cameron-Burr, K. T., Shaham, Y. & Kiyatkin, E. A. Intravenous heroin induces rapid brain hypoxia and hyperglycemia that precede brain metabolic response. eNeuro https:\/\/doi.org\/10.1523\/ENEURO.0151-17.2017 (2017).","journal-title":"eNeuro"},{"key":"10299_CR92","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/npp.2017.181","volume":"43","author":"E Solis Jr","year":"2018","unstructured":"Solis, E. Jr, Cameron-Burr, K. T., Shaham, Y. & Kiyatkin, E. A. Fentanyl-induced brain hypoxia triggers brain hyperglycemia and biphasic changes in brain temperature. Neuropsychopharmacology 43, 810\u2013819 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"10299_CR93","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/00001756-199805110-00004","volume":"9","author":"B Rho","year":"1998","unstructured":"Rho, B. & Glick, S. D. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. NeuroReport 9, 1283\u20131285 (1998).","journal-title":"NeuroReport"},{"key":"10299_CR94","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejphar.2005.03.005","volume":"513","author":"OD Taraschenko","year":"2005","unstructured":"Taraschenko, O. D., Panchal, V., Maisonneuve, I. M. & Glick, S. D. Is antagonism of \u03b13\u03b24 nicotinic receptors a strategy to reduce morphine dependence?. Eur. J. Pharmacol. 513, 207\u2013218 (2005).","journal-title":"Eur. J. Pharmacol."},{"key":"10299_CR95","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.pbb.2011.03.004","volume":"98","author":"LF Vendruscolo","year":"2011","unstructured":"Vendruscolo, L. F. et al. Escalation patterns of varying periods of heroin access. Pharmacol. Biochem. Behav. 98, 570\u2013574 (2011).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10299_CR96","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/npp.2017.172","volume":"43","author":"JCM Vendruscolo","year":"2018","unstructured":"Vendruscolo, J. C. M. et al. Compulsive-like sufentanil vapor self-administration in rats. Neuropsychopharmacology 43, 801\u2013809 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"10299_CR97","unstructured":"Wouters, E. et al. in Receptor\u2013Receptor Interactions in the Central Nervous System (eds Fuxe, K. & Borroto-Escuela, D. O.) 239\u2013250 (Springer, 2018)."},{"key":"10299_CR98","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/B978-0-12-418687-3.00018-5","volume":"529","author":"PA Longo","year":"2013","unstructured":"Longo, P. A., Kavran, J. M., Kim, M. S. & Leahy, D. J. Transient mammalian cell transfection with polyethylenimine (PEI). Methods Enzymol. 529, 227\u2013240 (2013).","journal-title":"Methods Enzymol."},{"key":"10299_CR99","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013d553 (2025).","journal-title":"Nucleic Acids Res."}],"updated-by":[{"DOI":"10.1038\/s41586-026-10552-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10299-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:02:08Z","timestamp":1777550528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10299-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":99,"journal-issue":{"issue":"8112","published-print":{"date-parts":[[2026,4,30]]}},"alternative-id":["10299"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10299-9","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-026-10552-1","URL":"https:\/\/doi.org\/10.1038\/s41586-026-10552-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L.G., A.S., M.H.B., K.C.R. and M.M. are listed as co-inventors on a patent application (WO2024196438A1) for the use of novel fluorinated etonitazene analogues in anaesthesia, pain and substance use disorders. J.L.G., A.S., M.H.B., K.C.R. and M.M. have assigned any potential patent rights to the US government but will share a percentage of any royalties that may be received by the government. G.S. is a co-founder of and consultant for Deep Apple Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}